Insights into the role of the resolvin D2-GPR18 signaling axis in cardiovascular physiology and disease.

Q1 Pharmacology, Toxicology and Pharmaceutics Advances in pharmacology Pub Date : 2023-01-01 DOI:10.1016/bs.apha.2022.12.005
Matthew Spite, Gabrielle Fredman
{"title":"Insights into the role of the resolvin D2-GPR18 signaling axis in cardiovascular physiology and disease.","authors":"Matthew Spite,&nbsp;Gabrielle Fredman","doi":"10.1016/bs.apha.2022.12.005","DOIUrl":null,"url":null,"abstract":"<p><p>Non-resolving inflammation is an underpinning of cardiovascular diseases including atherosclerosis. The resolution of inflammation is an active and highly coordinated process that involves the generation of specialized pro-resolving mediators (SPMs), and other factors including proteins, gases, and nucleotides. SPMs comprise a superfamily of lipid mediators that includes lipoxins, resolvins, maresins and protectins. SPMs act through distinct G protein-coupled receptors (GPCRs) and have been extensively studied in animal models of cardiovascular diseases. An emerging body of literature suggests that SPMs have protective roles in atherosclerosis as demonstrated using specific SPM as well as mice deficient in their receptors. This review will highlight a relatively new pro-resolving signaling axis, namely Resolvin D2-GPR18, and how understanding detailed mechanisms and cellular specificity of this signaling axis may help inform the development of more targeted pro-resolution therapies for atherosclerosis and related cardiovascular pathologies.</p>","PeriodicalId":7366,"journal":{"name":"Advances in pharmacology","volume":"97 ","pages":"257-281"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/bs.apha.2022.12.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Non-resolving inflammation is an underpinning of cardiovascular diseases including atherosclerosis. The resolution of inflammation is an active and highly coordinated process that involves the generation of specialized pro-resolving mediators (SPMs), and other factors including proteins, gases, and nucleotides. SPMs comprise a superfamily of lipid mediators that includes lipoxins, resolvins, maresins and protectins. SPMs act through distinct G protein-coupled receptors (GPCRs) and have been extensively studied in animal models of cardiovascular diseases. An emerging body of literature suggests that SPMs have protective roles in atherosclerosis as demonstrated using specific SPM as well as mice deficient in their receptors. This review will highlight a relatively new pro-resolving signaling axis, namely Resolvin D2-GPR18, and how understanding detailed mechanisms and cellular specificity of this signaling axis may help inform the development of more targeted pro-resolution therapies for atherosclerosis and related cardiovascular pathologies.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
解析蛋白D2-GPR18信号轴在心血管生理和疾病中的作用
不消炎是包括动脉粥样硬化在内的心血管疾病的基础。炎症的消退是一个积极和高度协调的过程,涉及产生专门的促消退介质(SPMs)和其他因素,包括蛋白质、气体和核苷酸。SPMs包含一个脂质介质超家族,包括脂质毒素、分解蛋白、蛋白和保护蛋白。SPMs通过不同的G蛋白偶联受体(gpcr)起作用,并在心血管疾病的动物模型中得到广泛研究。越来越多的文献表明,SPM在动脉粥样硬化中具有保护作用,这是通过使用特异性SPM和缺乏其受体的小鼠来证明的。这篇综述将重点介绍一个相对较新的促溶解信号轴,即Resolvin D2-GPR18,以及了解该信号轴的详细机制和细胞特异性如何有助于开发更有针对性的促溶解治疗动脉粥样硬化和相关心血管疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Advances in pharmacology
Advances in pharmacology Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
9.10
自引率
0.00%
发文量
45
期刊最新文献
Drug discovery strategy for TAK-418, a specific inhibitor of LSD1 enzyme activity, as a novel therapy for autism. Evolution of D-amino acid oxidase inhibitors: From concept to clinic. Inhibition of brain glutamate carboxypeptidase II (GCPII) to enhance cognitive function. Modulatory and protective effects of prolyl hydroxylase domain inhibitors in the central nervous system. Neutral sphingomyelinase 2: A promising drug target for CNS disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1